<DOC>
	<DOCNO>NCT00005997</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness rebeccamycin analogue treat patient advance liver and/or biliary cancer .</brief_summary>
	<brief_title>Rebeccamycin Analogue Treating Patients With Advanced Liver and/or Biliary Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance hepatobiliary carcinoma treat rebeccamycin analogue . - Assess toxicity associate drug patient population . - Evaluate survival patient population treat drug . - Determine pharmacokinetics drug patient population . OUTLINE : This partial dose-escalation study . Patients receive rebeccamycin analogue IV 1 hour daily day 1-5 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients assign 1 2 cohort accord hepatic dysfunction . ( Cohort I close accrual 11/1/03 . ) - Cohort I ( close accrual 11/1/03 ) : Patients receive fix dose rebeccamycin analogue . - Cohort II : Cohorts 3-6 patient receive escalate dos rebeccamycin analogue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 6-37 month .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance hepatobiliary carcinoma amenable conventional surgery Gall bladder carcinoma Cholangiocarcinoma Carcinoma ampulla Hepatocellular carcinoma ( eligible cohort II ) Measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 3 mg/dL Cohort I ( close accrual 11/1/03 ) Bilirubin great 1.5 mg/dL AST great 2.5 time upper limit normal ( ULN ) Cohort II Bilirubin great 1.5 mg/dL less 3 mg/dL OR Bilirubin great 1.5 mg/dL AND AST great 2.5 time ULN Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy cholangiocarcinoma hepatobiliary carcinoma Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent combination antiviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>